On March 28th, Zaiding Pharmaceutical announced on the Hong Kong Stock Exchange that its annual revenue for 2024 was 399 million US dollars, compared to 267 million US dollars in the same period last year; The net product revenue for the year increased by $130.9 million (or 49%) to $397.6 million; The net loss for the year decreased by $77.5 million (or 23%) to $257.1 million, mainly due to product revenue growing faster than net operating expenses, offset by a decrease in interest income and an increase in exchange losses.
Scan code to share